Verve Therapeutics, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
23.83 |
45.04 |
16.08 |
15.00 |
21.00 |
9.00 |
| Przychód Δ r/r |
0.00% |
89.02% |
-64.30% |
-6.72% |
40.00% |
-57.14% |
| Przychód (min) |
19.46 |
25.83 |
16.08 |
10.21 |
14.30 |
6.13 |
| Przychód (max) |
29.94 |
57.66 |
16.08 |
22.49 |
31.48 |
13.49 |
| EBITDA (średnia) |
-4.77 |
-9.01 |
-3.22 |
-3.00 |
-4.20 |
-1.80 |
| EBIT (średnia) |
-4.77 |
-9.01 |
-3.22 |
-3.00 |
-4.20 |
-1.80 |
| EBIT % |
-20.00% |
-20.00% |
-20.00% |
-20.00% |
-20.00% |
-20.00% |
| Zysk netto (średni) |
-206.29 |
-213.04 |
-274.53 |
-165.27 |
-64.39 |
-333.81 |
| Zysk netto % |
-865.72% |
-472.97% |
-1707.30% |
-1101.78% |
-306.61% |
-3708.95% |
| EPS (średnia) |
-2.43 |
-2.51 |
-3.11 |
-1.90 |
-0.76 |
-3.94 |
| Liczba analityków (Przychody) |
8 |
3 |
6 |
6 |
2 |
5 |
| Liczba analityków (EPS) |
8 |
5 |
5 |
5 |
2 |
1 |
| symbol |
VERV |
VERV |
VERV |
VERV |
VERV |
VERV |